View ValuationPfizer 将来の成長Future 基準チェック /16Pfizer利益と収益がそれぞれ年間12.5%と9%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18% 12.5%なると予測されています。主要情報12.5%収益成長率12.47%EPS成長率Pharmaceuticals 収益成長16.7%収益成長率9.0%将来の株主資本利益率18.00%アナリストカバレッジLow最終更新日15 May 2026今後の成長に関する最新情報Price Target Changed • Aug 01Price target increased by 11% to ₹5,477Up from ₹4,953, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of ₹5,640. Stock is up 41% over the past year. The company is forecast to post earnings per share of ₹139 for next year compared to ₹121 last year.Price Target Changed • May 17Price target decreased by 7.9% to ₹4,595Down from ₹4,988, the current price target is an average from 5 analysts. New target price is 20% above last closing price of ₹3,817. Stock is down 11% over the past year. The company posted earnings per share of ₹136 last year.Price Target Changed • Jun 14Price target decreased to ₹5,201Down from ₹5,647, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹4,149. Stock is down 25% over the past year. The company posted earnings per share of ₹134 last year.すべての更新を表示Recent updatesReported Earnings • May 15Full year 2026 earnings released: EPS: ₹158 (vs ₹168 in FY 2025)Full year 2026 results: EPS: ₹158 (down from ₹168 in FY 2025). Revenue: ₹25.2b (up 10% from FY 2025). Net income: ₹7.22b (down 5.9% from FY 2025). Profit margin: 29% (down from 34% in FY 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year.Buy Or Sell Opportunity • May 14Now 21% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₹4,681. The fair value is estimated to be ₹3,855, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 8.5% in the next 2 years.お知らせ • May 13Pfizer Limited announces Annual dividend, payable on August 27, 2026Pfizer Limited announced Annual dividend of INR 75.0000 per share payable on August 27, 2026, ex-date on July 17, 2026 and record date on July 17, 2026.Reported Earnings • Feb 10Third quarter 2026 earnings released: EPS: ₹40.42 (vs ₹27.89 in 3Q 2025)Third quarter 2026 results: EPS: ₹40.42 (up from ₹27.89 in 3Q 2025). Revenue: ₹6.83b (up 27% from 3Q 2025). Net income: ₹1.42b (up 11% from 3Q 2025). Profit margin: 21% (down from 24% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 20Pfizer Limited Announces Senior Management Personnel ChangesPfizer Limited announced the appointment of Mr. Nilesh Pendse as Category Lead – Vaccines of the Company with effect from February 1, 2026. Mr. Pendse shall accordingly be a Senior Management Personnel of the company effective the said date. Mr. Pendse joined Pfizer Products India Private Limited in 2024, where he led the Oncology Business, focusing on strategic growth, market access, and stakeholder engagement to advance cancer care. Prior to joining Pfizer Products India Private Limited, Mr. Pendse held leadership roles at Boehringer Ingelheim and Novartis where he managed diabetes and neurosciences Divisions, with a focus on sales, marketing, and franchise operations. In addition, Mr. Pendse comes from consulting background experience with firms such as Boston Consulting Group, Ernst & Young (EY) and Accenture, where he led projects related to strategy, revenue acceleration, and business transformation. Mr. Nilesh Pendse holds an MBA in Marketing from Jamnalal Bajaj Institute of Management Studies and a Bachelor’s degree in Electronics Engineering from the University of Mumbai. The company also announced that Mr. Manikantan Seshadrinathan – Category Lead, Hospitals & Rare Disease will transition to another role within the Pfizer Group Companies effective February 1, 2026, and shall accordingly cease to be a Senior Management Personnel of the Company effective January 31, 2026. Mr. Prashant Mahalingam, Category Lead – Internal Medicine, will take up additional responsibility of the Hospitals Business of the Company and shall be redesignated as Category Lead – Internal Medicine & Hospitals, effective February 1, 2026.分析記事 • Dec 30Pfizer Limited's (NSE:PFIZER) Price Is Out Of Tune With EarningsWith a median price-to-earnings (or "P/E") ratio of close to 25x in India, you could be forgiven for feeling...分析記事 • Nov 25Pfizer's (NSE:PFIZER) Solid Profits Have Weak FundamentalsPfizer Limited's ( NSE:PFIZER ) robust earnings report didn't manage to move the market for its stock. Our analysis...New Risk • Nov 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹41.32 (vs ₹34.61 in 2Q 2025)Second quarter 2026 results: EPS: ₹41.32 (up from ₹34.61 in 2Q 2025). Revenue: ₹6.42b (up 9.1% from 2Q 2025). Net income: ₹1.89b (up 19% from 2Q 2025). Profit margin: 29% (up from 27% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.分析記事 • Sep 13Pinning Down Pfizer Limited's (NSE:PFIZER) P/E Is Difficult Right NowWith a median price-to-earnings (or "P/E") ratio of close to 28x in India, you could be forgiven for feeling...Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹41.91 (vs ₹32.94 in 1Q 2025)First quarter 2026 results: EPS: ₹41.91 (up from ₹32.94 in 1Q 2025). Revenue: ₹6.03b (up 7.1% from 1Q 2025). Net income: ₹1.92b (up 27% from 1Q 2025). Profit margin: 32% (up from 27% in 1Q 2025). Revenue is forecast to grow 7.5% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 8% per year.New Risk • Jul 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.お知らせ • Jul 02Pfizer Limited Announces Directorate ChangesPfizer Limited announced that Ms. Shilpi Singh, Director - People Experience has tendered her resignation from the services of the Company with effect from August 14, 2025 (close of business), to pursue opportunities outside Pfizer Limited. Ms. Singh shall accordingly cease to be a Senior Management Personnel effective the said date. It is further informed that the Board of Directors, upon recommendation of the Nomination & Remuneration Committee has appointed Ms. Reshma Parida, currently the Senior Director- People Experience for APAC & AfME and SBO APAC Cluster, as Senior Director - People Experience of the Company with effect from August 1, 2025. Ms. Reshma Parida shall be a Senior Management Personnel of the Company, effective the said date. Ms. Parida is an accomplished professional with close to 3 decades of expertise in Human Resources field. Ms. Parida's areas of expertise include strategic business partnership, transformation management, organization design and effectiveness, talent and leadership coaching, diversity and inclusion, employee engagement, mergers and acquisitions, execution excellence, and well-being. Ms. Parida has undertaken varied roles of increasing responsibilities in Pfizer for about 5 years in the People Experience function. Ms. Parida began her career in Pfizer as Regional HR Lead for APAC region in August 2020 and has taken up the additional responsibility of HR Lead for Global API, SBO APAC Cluster and Global Small Molecule Operations from 2021. In her current role in Pfizer Global Supply (PGS), she leads the People Experience function for APAC & AfME Region and SBO APAC Cluster. Prior to her role with Pfizer, Ms. Parida has held senior positions at Teva Pharmaceuticals, Bristol Myers Squibb, and Mylan Pharmaceuticals. Ms. Reshma Parida holds a Bachelor of Science degree from Fergusson College, Pune, and a Masters' degree in Personnel Management from Pune University.Reported Earnings • Jul 02Full year 2025 earnings released: EPS: ₹168 (vs ₹121 in FY 2024)Full year 2025 results: EPS: ₹168 (up from ₹121 in FY 2024). Revenue: ₹22.8b (up 4.0% from FY 2024). Net income: ₹7.68b (up 39% from FY 2024). Profit margin: 34% (up from 25% in FY 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jun 30+ 2 more updatesPfizer Limited to Report Q4, 2026 Results on May 30, 2026Pfizer Limited announced that they will report Q4, 2026 results on May 30, 2026分析記事 • May 28Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 28%The Pfizer Limited ( NSE:PFIZER ) share price has done very well over the last month, posting an excellent gain of 28...分析記事 • May 26Pfizer (NSE:PFIZER) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfUnsurprisingly, Pfizer Limited's ( NSE:PFIZER ) stock price was strong on the back of its healthy earnings report...Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹5,148, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 24% over the past three years.お知らせ • May 20+ 2 more updatesPfizer Limited, Annual General Meeting, Jul 21, 2025Pfizer Limited, Annual General Meeting, Jul 21, 2025.Reported Earnings • May 20Full year 2025 earnings released: EPS: ₹168 (vs ₹121 in FY 2024)Full year 2025 results: EPS: ₹168 (up from ₹121 in FY 2024). Revenue: ₹24.5b (up 12% from FY 2024). Net income: ₹7.68b (up 39% from FY 2024). Profit margin: 31% (up from 25% in FY 2024). Revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.分析記事 • Mar 03Pfizer Limited's (NSE:PFIZER) Share Price Not Quite Adding UpWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") below 24x, you may consider Pfizer...お知らせ • Feb 14Pfizer Limited Announces Completion of Second Term for Sunil Lalbhai as an Independent Director, Chairman of the Stakeholders' Relationship Committee and Risk Management Committee and Member of the Audit CommitteePfizer Limited announced that Mr. Sunil Lalbhai has completed his second term as an Independent Director of the Company with effect from the end of the day on February 13, 2025. Consequent to Mr. Lalbhai's completion of term as an Independent Director, he ceased to be the Chairman of the Stakeholders' Relationship Committee and Risk Management Committee and Member of the Audit Committee.Reported Earnings • Feb 01Third quarter 2025 earnings released: EPS: ₹27.89 (vs ₹28.42 in 3Q 2024)Third quarter 2025 results: EPS: ₹27.89 (down from ₹28.42 in 3Q 2024). Revenue: ₹5.81b (up 7.6% from 3Q 2024). Net income: ₹1.28b (down 1.8% from 3Q 2024). Profit margin: 22% (down from 24% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat.お知らせ • Jan 31Pfizer Limited Announces Resignation of Amit Sharma as DirectorPfizer Limited announced resignation of Mr. Amit Sharma, as Director effective from close of business hours on January 31, 2025, to pursue opportunities outside Pfizer.お知らせ • Jan 18FeganScott Announces Class-Action Lawsuit Against Pfizer and ViatrisCalifornia woman has filed a class-action lawsuit claiming pharmaceutical giants Pfizer (PFE) and Viatris (VTRS), among others, manufactured and sold Depo-Provera, one of the most widely used forms of hormonal contraception, despite knowledge that it causes brain tumors. According to the complaint, studies dating back to the 1980s have shown a connection between hormones and brain tumors called intracranial meningiomas that the pharmaceutical giants should have known about. A March 2024 study published in the British Medical Journal cemented a positive correlation between medroxyprogesterone acetate (MPA), the synthetic hormone found in Depo-Provera, and the tumors. The study found that women using Depo-Provera are five times more likely to develop intracranial meningiomas when used for more than one year. The complaint states that at times, nearly a quarter of all sexually active women in the United States used Depo-Provera. Use of the popular contraceptive has historically been highest among women in at-risk populations, as it is relatively low-cost and less burdensome compared to other contraceptives. The suit cites a body of scientific studies published between the 1980s and 2024 that link Depo-Provera to the development of intracranial meningiomas, which FeganScott Attorney Lynn Ellenberger says both the brand and generic manufacturers should have been aware of and acted upon. The lawsuit, filed in the federal court in the Western District of Pennsylvania, seeks to establish a medical monitoring program for those in certain states who have received the Depo-Provera injection for at least one year. Individuals interested in learning more about their legal options are urged to contact FeganScott.分析記事 • Nov 28Some Confidence Is Lacking In Pfizer Limited's (NSE:PFIZER) P/EPfizer Limited's ( NSE:PFIZER ) price-to-earnings (or "P/E") ratio of 39.3x might make it look like a sell right now...お知らせ • Nov 15Pfizer Limited Appoints Mr. Chetan Solse as India Legal Lead, Effective November 18, 2024Pfizer Limited informed that the Board of Directors of the Company, upon recommendation of the Nomination and Remuneration Committee has appointed Mr. Chetan Solse as India Legal Lead of the Company effective November 18, 2024. Accordingly, Mr. Chetan Solse shall be a Senior Management Personnel of the Company effective November 18, 2024. Mr. Solse holds a Bachelor's Degree in Commerce and Law from the University of Mumbai and is a certified member of the Institute of Company Secretaries of India (ICSI) and the Institute of Chartered Secretaries and Administrators (ICSA), UK. Mr. Solse is an accomplished legal counsel with over two decades of expertise in corporate legal advisory, litigation management, ethics & compliance, and risk management particularly within the healthcare and FMCG sectors. Mr. Solse joins the Company from Roche Diagnostics India Private Limited where he served as Head Legal & Risk Management (India & Neighboring Markets). Prior to his role with Roche Diagnostics India Private Limited, Mr. Solse has held senior positions at Parle Agro Private Limited, Diageo India Private Limited and Edwards Life Sciences (India) Private Limited.お知らせ • Nov 11Pfizer Limited Announces Board and Committee ChangesPfizer Limited announced that Mr. Pradip Shah and Mr. Uday Khanna, have completed their term as Independent Directors of the Company with effect from the end of the day on November 9, 2024. Consequent to Mr. Khanna's completion of term as an Independent Director, he ceased to be the Chairman of the Audit Committee and Nomination & Remuneration Committee and Member of the Stakeholders' Relationship Committee. an intimation was given that the Board of Directors of the Company, upon recommendation of the Nomination and Remuneration Committee, had appointed Mr. Pradip Shah as a Non-Executive Non-Independent Director with effect from November 10, 2024, liable to retire by rotation. It may also be noted that the said appointment was approved by the shareholders of the Company at the 73 Annual General Meeting of the Company held on August 28, 2024. Mr. Pradip Shah shall continue to be the Chairman of the Board of Directors, Corporate Social Responsibility Committee and a Member of the Audit Committee and the Nomination and Remuneration Committee. Mr. Pradip Shah is the founder and Chairman of IndAsia Fund Advisors Private Limited. He is also the co-founder of www.Grow-Trees.com. Mr. Pradip Shah holds an MBA from the Harvard Business School. He is also a Chartered Accountant and a Cost Accountant and ranked first in India in the Chartered Accountancy Examination. Mr. Shah is the ex-Managing Director of CRISIL, India's first and the largest credit rating agency. Prior to founding CRISIL, Mr. Pradip Shah assisted in founding the Housing Development Finance Corporation (HDFC) in 1977. Mr. Shah has also served as a consultant to USAID, the World Bank and the Asian Development Bank. He has also a member /Chairman of various prestigious committees/commissions such as Banks Board Bureau, IFSC International Retail Business Development Committee, Western Region Board of Reserve Bank of India. Mr. Shah is a Director on the Board of several reputed companies including Kansai Nerolac Paints Limited, Sonata Software Limited, BASF (India) Limited, Bajaj Auto Limited.お知らせ • Nov 05Pfizer Limited Announces Executive Appointments, Effective November 7, 2024Pfizer Limited announced Mr. Deepak Rakheja, Category Lead Internal Medicine has been appointed as Strategic Partnerships, Channel Development and International Neighbouring Markets Lead, effective November 7, 2024. Mr. Rakheja shall continue to be a Senior Management Personnel. Mr. Deepak Rakheja holds Master's in Business Administration Degree from HEC Paris Business School. Mr. Rakheja also holds a Master of Economics Degree from University of Delhi. Mr. Deepak Rakheja has during his 15 years of tenure with Pfizer, helmed roles of increased scope, responsibility & complexity, including Category Lead Internal Medicine, Commercial roles, Sales Logistics & Demand Management, Business Operations, Field Force Effectiveness, Training, and Commercial Compliance. Mr. Rakheja also lead Pfizer's Global Commercial Operations (GCO) for Africa, Middle East & India. Prior to this he had also served as the Commercial Director for Growth Markets (Iran, Iraq, Syria & Yemen) and the Strategic Alliances Gulf Levant Markets. The company also announced appointment of Mr. Prashant Mahalingam as Category Lead Internal Medicine effective November 7, 2024. Mr. Prashant Mahalingam shall be a Senior Management Personnel effective the said date. Mr. Prashant Mahalingam holds a Bachelors in Technology (Chemical Engineering) from IIT Madras, Post Graduate Degree in Management from IIM Calcutta and Executive Education Innovation Consortium from Tuck School of Business, University of Dartmouth. Mr. Mahalingam is a versatile and transformative business leader with over 25 years of experience across General Management, Sales, Marketing, Human Resources, Supply Chain, Digital Transformation, Analytics, and E-Commerce, primarily in the FMCG and Pharmaceutical sectors. Mr. Mahalingam joins the Company from Dr. Reddy's Laboratories Limited (DRL), where he served as the Cluster Head for the Acute Therapies (RX) and Consumer Health business. Prior to his role with DRL Mr. Mahalingam served as Commercial Head for Johnson & Johnson's Consumer health business in Malaysia and Singapore markets. Mr. Mahalingam has significant experience in leading large teams, turning around businesses to deliver market-beating and sustainable growth, and spearheading new innovation-led digital ventures.Reported Earnings • Oct 29Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024)Second quarter 2025 results: EPS: ₹34.61 (up from ₹32.56 in 2Q 2024). Revenue: ₹5.89b (up 2.3% from 2Q 2024). Net income: ₹1.58b (up 6.3% from 2Q 2024). Profit margin: 27% (up from 26% in 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year.Board Change • Sep 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Lakshmanan Kumar was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.分析記事 • Aug 31We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...お知らせ • Aug 30Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024Pfizer Limited approved to declare a dividend of INR 35 (350%) per equity share for the financial year ended March 31, 2024, at its AGM held on August 28, 2024.Declared Dividend • Aug 09Dividend of ₹35.00 announcedShareholders will receive a dividend of ₹35.00. Ex-date: 21st August 2024 Payment date: 6th September 2024 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (29% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has increased by an average of 12% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 12% over the next year, which should provide support to the dividend and adequate earnings cover.お知らせ • Aug 08Pfizer Limited, Annual General Meeting, Aug 28, 2024Pfizer Limited, Annual General Meeting, Aug 28, 2024, at 15:00 Indian Standard Time.お知らせ • Aug 07+ 2 more updatesPfizer Limited to Report Q2, 2025 Results on Nov 14, 2024Pfizer Limited announced that they will report Q2, 2025 results on Nov 14, 2024分析記事 • Aug 07Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%Despite an already strong run, Pfizer Limited ( NSE:PFIZER ) shares have been powering on, with a gain of 25% in the...Price Target Changed • Aug 01Price target increased by 11% to ₹5,477Up from ₹4,953, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of ₹5,640. Stock is up 41% over the past year. The company is forecast to post earnings per share of ₹139 for next year compared to ₹121 last year.Reported Earnings • Jul 30First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)First quarter 2025 results: EPS: ₹32.94 (up from ₹20.44 in 1Q 2024). Revenue: ₹6.05b (up 14% from 1Q 2024). Net income: ₹1.51b (up 61% from 1Q 2024). Profit margin: 25% (up from 18% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 2% per year.お知らせ • Jul 22Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024Pfizer Limited announced that they will report Q1, 2025 results on Jul 29, 2024分析記事 • May 25Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)Pfizer Limited's ( NSE:PFIZER ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...Reported Earnings • May 18Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)Full year 2024 results: EPS: ₹121 (down from ₹136 in FY 2023). Revenue: ₹23.7b (down 2.1% from FY 2023). Net income: ₹5.51b (down 12% from FY 2023). Profit margin: 23% (down from 26% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • May 18Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024Pfizer Limited announced that at its Board of Directors has at its Meeting held on May 17, 2024, recommended a dividend of INR 35/- per equity share of INR 10/- each (350%) for the financial year ended March 31, 2024. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 6, 2024.お知らせ • May 08Pfizer Limited to Report Q4, 2024 Results on May 17, 2024Pfizer Limited announced that they will report Q4, 2024 results on May 17, 2024お知らせ • Apr 03+ 1 more updatePfizer Limited Appoints Amit Agarwal as Chief Financial OfficerPfizer Limited announced the appointment of Mr. Amit Agarwal as a Whole-time Director of the Company designated as Executive Director Finance & Chief Financial Officer for a period of 5 years with effect from February 26, 2024, by way of an `Ordinary Resolution'.お知らせ • Mar 28China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder CancerAstellas Pharma Inc. announced that on March 27, 2024 the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for enfortumab vedotin with KEYTRUDA (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If approved, enfortumab vedotin with KEYTRUDA has the potential to change the treatment paradigm, becoming the first combination treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC. Urothelial cancer (UC) encompasses cancers of both the lower urinary tract (bladder and urethra) and upper tract (ureter and renal pelvis), with disease that originates in the lower tract accounting for 90% to 95% of all UC cases. Globally, approximately 614,000 new cases of bladder cancer and approximately 220,000 deaths are reported annually. It is estimated that approximately 93,000 people in China were diagnosed with bladder cancer and approximately 41,000 deaths were reported in 2022. The sBLA for the first-line use of this combination is based on results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39). The study found that the combination improved overall survival (OS) and progression-free survival (PFS) with statistically significant and clinically meaningful results in patients with previously untreated la/mUC compared to platinum-containing chemotherapy. The safety results were consistent with those previously reported with this combination, and no new safety issues were identified. The NMPA is also reviewing enfortumab vedotin as a treatment for patients with locally advanced or metastatic urothelial cancer (la/mUC) who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency is reviewing the enfortumab vedotin in combination with pembrolizumab therapy, as well as Japan's Ministry of Health, Labour and Welfare (MHLW). The U.S. Food and Drug Administration approved the combination therapy in December 2023.分析記事 • Feb 13Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)Third quarter 2024 results: EPS: ₹28.42 (down from ₹32.93 in 3Q 2023). Revenue: ₹5.76b (down 7.4% from 3Q 2023). Net income: ₹1.30b (down 14% from 3Q 2023). Profit margin: 23% (down from 24% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.お知らせ • Feb 09Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024Pfizer Limited informed that Mr. Satyen Amin, Lead - Market Access has tendered his resignation from employment of the Company with effect from March 31, 2024, to pursue an opportunity outside Pfizer Limited. Mr. Satyen Amin shall accordingly cease to be a Senior Management Personnel effective the said date.お知らせ • Feb 01Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024Pfizer Limited announced that they will report Q3, 2024 results on Feb 09, 2024分析記事 • Jan 17Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share PriceWith a price-to-earnings (or "P/E") ratio of 37.4x Pfizer Limited ( NSE:PFIZER ) may be sending bearish signals at the...お知らせ • Nov 17Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023Pfizer Limited informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company appointed Ms. Aditi Mehta as Category Lead, Vaccines effective December 1, 2023. Accordingly, Ms. Aditi Mehta shall be a Senior Management Personnel effective the said date. Ms. Aditi Mehta is a Gold Medalist in Bachelor of Pharmacy from K.M Kundnani College of Pharmacy, Mumbai. Ms. Aditi Mehta is a seasoned pharmaceutical professional with over 13 years of experience in pharmaceutical marketing, strategy & research. Ms. Mehta had a decade long stint with Pfizer Products India Pvt. Ltd., (Pfizer Inc.'s wholly owned subsidiary in India) where she held positions of increasing responsibilities. In her role as Category Lead for Oncology business, she was responsible for the development and execution of the strategy for the Oncology portfolio for India market. Prior to this, Ms. Mehta had a two-year stint with Bristol Myers Squibb as a Business Analyst. Ms. Mehta is proud receipt of various accolades and awards, including the Medico-Marketing Excellence Award 2017 by Pfizer India Country Leadership, PfizerGlobal Commercial Award in 2019 for Breast Cancer Access initiatives in India, e4M Health & Wellness Marketing Award 2023 for World Cancer Day Awareness Campaign. Most recently, she has also been selected among the Top 100 Inspiring Women Leaders in Pfizer.お知らせ • Nov 15Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023Pfizer Limited announced that Mr. Milind Patil has resigned as a Director on the Board with effect from close of business on November 13, 2023, consequent to the expiry of his 5 year term as Executive Director - Finance effective the said date and his upcoming retirement from the services of the Company effective November 30, 2023. Pursuant to the above, Mr. Patil shall cease to be a Member of the Corporate Social Responsibility Committee, Risk Management Committee and Board Administrative & Share Transfer Committee of the Board effective close of business on November 13, 2023. It may be noted that Mr. Patil shall continue to serve as the Chief Financial Officer of the Company until his retirement on November 30, 2023.お知らせ • Oct 29Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of DirectorsPfizer Limited announced that Mr. Samir Kazi has resigned as a Director from the Board of Directors of the Company effective close of business September 12, 2023. to pursue an opportunity outside Pfizer Limited. Consequently, Mr. Samir Kazi has resigned as a Director from the Board of Directors of the Company, with effect from the close of business on September 12, 2023. Pursuant to the above, Mr. Kazi shall cease to be a Member of the Corporate Social Responsibility Committee, Stakeholders' Relationship Committee and Board Administrative & Share Transfer Committee of the Board effective close of business on September 12, 2023. The effective date of resignation of Mr. Samir Kazi as an employee shall be from such date as may be mutually agreed between the Company and Mr. Kazi.Reported Earnings • Oct 29Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)Second quarter 2024 results: EPS: ₹32.56 (down from ₹67.99 in 2Q 2023). Revenue: ₹6.11b (down 4.1% from 2Q 2023). Net income: ₹1.49b (down 52% from 2Q 2023). Profit margin: 24% (down from 49% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 8.7% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.お知らせ • Oct 19Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023Pfizer Limited announced that they will report Q2, 2024 results on Oct 28, 2023お知らせ • Sep 07Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner LeadPfizer Limited informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has appointed Mr. Chaitanya Nadkarni as India Digital Client Partner Lead effectiveSeptember 11, 2023. Accordingly, Mr. Chaitanya Nadkarni shall be a Senior Management Personnel effective the said date. Mr. Chaitanya Nadkarni brings over 26 years of experience in the field of IT and Digital solutions. During his 11 years tenure in Novartis Healthcare he has been instrumental in devising IT Roadmaps for various countries in alignment with business initiatives and Global/Regional (Asia Pacific, Middle East & Africa) IT & Digital Strategy. He rolled out several digital tools to the Marketing and Sales teams for impactful omni-channel engagement with HCPs. Mr. Chaitanya Nadkarni had also established a Digital Governance Process, Asset Roll-out management and created awareness about Information Security through internal campaigns. Mr. Chaitanya Nadkarni holds a bachelor's degree in Engineering and a MBA in Marketing. Mr. Chaitanya Nadkarni has extensively worked in various industries such as IT, Insurance, Consulting and has been with Pharmaceutical Industry for over 12 plus years.お知らせ • Aug 22Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023Pfizer Limited announced that at its Annual General Meeting of the Company held on August 18, 2023, approved to declare a final dividend of INR 40 (400%) per equity share for the financial year ended March 31, 2023.New Risk • Aug 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.1% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.お知らせ • Aug 18Pfizer Limited Announces Change in Management, Effective September 1, 2023Pfizer Limited announced that Mr. Manish Mishra Category Lead, Vaccines will be transitioning to a different role within Pfizer Group effective September 1, 2023, and shall accordingly cease to be a Senior Management Personnel effective the said date. Ms. Sudeshna Mitra Healthcare Solutions Partner Lead will be moving to a different role within the Company effective September 1, 2023, and shall accordingly cease to be a Senior Management Personnel from the said date.お知らせ • Aug 05Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023Pfizer Limited announced that they will report Q1, 2024 results on Aug 11, 2023Upcoming Dividend • Aug 04Upcoming dividend of ₹40.00 per share at 0.9% yieldEligible shareholders must have bought the stock before 11 August 2023. Payment date: 16 September 2023. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (0.9%).Reported Earnings • Jul 29Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)Full year 2023 results: EPS: ₹136 (up from ₹134 in FY 2022). Revenue: ₹24.2b (down 7.1% from FY 2022). Net income: ₹6.24b (up 1.9% from FY 2022). Profit margin: 26% (up from 24% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Jul 29Pfizer Limited, Annual General Meeting, Aug 18, 2023Pfizer Limited, Annual General Meeting, Aug 18, 2023, at 14:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended March 31, 2023, including the Reports of the Board of Directors and Auditors thereon; to declare a final dividend of INR 40/- (400%) per equity share for the financial year ended March 31, 2023; to consider appointment of a Director in place of Mr. Samir Kazi (DIN: 07184083), who retires by rotation and being eligible, offers himself for re-appointment; to consider revision in the limit of commission payable to Non-executive Directors; and to consider and ratify the remuneration payable to Messrs. RA & co., cost Accountants for the financial year ending March 31, 2024.お知らせ • Jul 28Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023Pfizer Limited proposed final dividend of INR 40 (400%) per equity share for the financial year ended March 31, 2023.お知らせ • May 19Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm InjectionsPfizer Limited has decided to initiate a voluntary recall of(i) Magnex 1gm, 2gm; (ii) Magnex Forte 1.5gm, 3gm; (iii) Zosyn 4.5gm; and (iv) Magnamycin 250mg, 1gm, 2gm injections manufactured by Astral SteriTech Private Limited ("Astral") and marketed/distributed by Pfizer Limited ("the Company"). Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. The Company was informed by its contract manufacturer in India, Astral SteriTech Private Ltd, that it has observed an out-of-specification during a routine environmental monitoring of its manufacturing block. Astral manufactures three products for Pfizer, namely, Magnex, Magnamycin and Zosyn. While this issue is presently being investigated, out of an abundance of caution, Pfizer has decided to voluntarily recall from the market, all batches of these three products. Pfizer is taking all necessary steps to resolve the situation. The above voluntary recall is likely to have an impact on the revenue and profitability of the Company. The said Products recorded a sale of INR 1,390 million for the year ended on March 31, 2023.Price Target Changed • May 17Price target decreased by 7.9% to ₹4,595Down from ₹4,988, the current price target is an average from 5 analysts. New target price is 20% above last closing price of ₹3,817. Stock is down 11% over the past year. The company posted earnings per share of ₹136 last year.お知らせ • May 16+ 1 more updatePfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023Pfizer Limited the Board of Directors meeting held on May 15, 2023, recommended a final dividend of INR 35 per equity share of INR 10 each (350%) for the financial year ended March 31, 2023. The said final dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 16, 2023.Reported Earnings • May 16Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)Full year 2023 results: EPS: ₹136 (up from ₹134 in FY 2022). Revenue: ₹25.3b (down 3.3% from FY 2022). Net income: ₹6.24b (up 1.9% from FY 2022). Profit margin: 25% (up from 23% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • May 06Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023Pfizer Limited announced that they will report fiscal year 2023 results on May 15, 2023分析記事 • Mar 15Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)Third quarter 2023 results: EPS: ₹32.93 (up from ₹31.46 in 3Q 2022). Revenue: ₹6.22b (down 8.0% from 3Q 2022). Net income: ₹1.51b (up 4.7% from 3Q 2022). Profit margin: 24% (up from 21% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Feb 10+ 2 more updatesPfizer India Appoints Meenakshi Nevatia as CEOPfizer India has announced the appointment of Meenakshi Nevatia as its new CEO and Managing Director, effective from 3 April, 2023. Nevatia will serve in this role for the next five years. Meenakshi Nevatia has been in the healthcare, medical technology, and pharmaceutical industries for over 25 years, holding various key global leadership positions. She is recognised as a medical device leader and has a strong passion for improving healthcare. In her previous role as Vice President and Managing Director of Stryker India, Nevatia was responsible for building the company's business strategy and setting it up for long-term growth in the Indian market. Last year in August, she was appointed as the chairperson for India Executive Committee of the Asia Pacific Medical Technology Association (APACMed).Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)Second quarter 2023 results: EPS: ₹67.99 (up from ₹31.25 in 2Q 2022). Revenue: ₹6.37b (flat on 2Q 2022). Net income: ₹3.11b (up 118% from 2Q 2022). Profit margin: 49% (up from 23% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Executive Director of Legal & Executive Director Samir Kazi was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)Second quarter 2023 results: EPS: ₹67.99 (up from ₹31.25 in 2Q 2022). Revenue: ₹6.62b (up 4.0% from 2Q 2022). Net income: ₹3.11b (up 118% from 2Q 2022). Profit margin: 47% (up from 23% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.Upcoming Dividend • Sep 12Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 19 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).Upcoming Dividend • Aug 11Upcoming dividend of ₹35.00 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 23 September 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (1.0%).Reported Earnings • Aug 06First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: ₹6.11b (down 19% from 1Q 2022). Net income: ₹325.5m (down 84% from 1Q 2022). Profit margin: 5.3% (down from 27% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Aug 05+ 1 more updatePfizer Limited to Report Q4, 2023 Results on May 29, 2023Pfizer Limited announced that they will report Q4, 2023 results on May 29, 2023分析記事 • Jul 20A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)How far off is Pfizer Limited ( NSE:PFIZER ) from its intrinsic value? Using the most recent financial data, we'll take...Buying Opportunity • Jul 12Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.9%. The fair value is estimated to be ₹5,170, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Earnings per share has grown by 9.3%.Price Target Changed • Jun 14Price target decreased to ₹5,201Down from ₹5,647, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹4,149. Stock is down 25% over the past year. The company posted earnings per share of ₹134 last year.Buying Opportunity • Jun 08Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.6%. The fair value is estimated to be ₹5,160, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Earnings per share has grown by 9.3%.業績と収益の成長予測NSEI:PFIZER - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202830,1829,2926,5487,81633/31/202727,5988,3155,1066,37133/31/202625,1977,2249,4239,676N/A12/31/202524,8238,536N/AN/AN/A9/30/202523,7538,3938,8049,098N/A6/30/202523,2158,086N/AN/AN/A3/31/202522,8147,6766,3166,598N/A12/31/202422,3616,155N/AN/AN/A9/30/202422,3816,1794,0144,165N/A6/30/202422,2476,085N/AN/AN/A3/31/202421,9325,5132,3792,568N/A12/31/202322,1925,021N/AN/AN/A9/30/202323,0105,2284,3225,040N/A6/30/202323,6326,849N/AN/AN/A3/31/202324,2486,2392,9073,557N/A12/31/202224,0416,201N/AN/AN/A9/30/202224,5836,1331,3411,493N/A6/30/202224,5714,452N/AN/AN/A3/31/202226,1106,1266,5186,671N/A12/31/202125,9615,873N/AN/AN/A9/30/202125,1375,8477,0187,147N/A6/30/202124,7285,731N/AN/AN/A3/31/202122,4044,9764,0964,273N/A12/31/202022,0585,001N/AN/AN/A9/30/202021,5054,9794,1294,004N/A6/30/202021,2215,208N/AN/AN/A3/31/202021,5175,0913,2113,232N/A12/31/201921,8535,156N/AN/AN/A9/30/201921,6095,085N/A1,716N/A6/30/201921,1364,500N/AN/AN/A3/31/201920,8154,291N/A978N/A12/31/201820,6584,241N/AN/AN/A9/30/201820,0853,794N/AN/AN/A6/30/201820,5993,947N/AN/AN/A3/31/201819,6853,601N/A3,318N/A12/31/201718,8663,236N/AN/AN/A9/30/201719,2152,987N/AN/AN/A6/30/201718,8603,139N/AN/AN/A3/31/201719,6633,368N/A3,288N/A12/31/201620,4532,737N/AN/AN/A9/30/201620,5952,711N/AN/AN/A6/30/201620,3502,276N/AN/AN/A3/31/201620,1233,050N/A3,455N/A12/31/201519,6491,680N/AN/AN/A9/30/201519,3341,460N/AN/AN/A6/30/201519,018861N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PFIZERの予測収益成長率 (年間12.5% ) は 貯蓄率 ( 6.9% ) を上回っています。収益対市場: PFIZERの収益 ( 12.5% ) Indian市場 ( 16.4% ) よりも低い成長が予測されています。高成長収益: PFIZERの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: PFIZERの収益 ( 9% ) Indian市場 ( 10.8% ) よりも低い成長が予測されています。高い収益成長: PFIZERの収益 ( 9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PFIZERの 自己資本利益率 は、3年後には低くなると予測されています ( 18 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 20:52終値2026/05/21 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pfizer Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Rohit Bhat360 ONE Capital Market Private LimitedSriraam RathiAnand Rathi Shares and Stock Brokers Limitednull nullAnand Rathi Shares and Stock Brokers Limited7 その他のアナリストを表示
Price Target Changed • Aug 01Price target increased by 11% to ₹5,477Up from ₹4,953, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of ₹5,640. Stock is up 41% over the past year. The company is forecast to post earnings per share of ₹139 for next year compared to ₹121 last year.
Price Target Changed • May 17Price target decreased by 7.9% to ₹4,595Down from ₹4,988, the current price target is an average from 5 analysts. New target price is 20% above last closing price of ₹3,817. Stock is down 11% over the past year. The company posted earnings per share of ₹136 last year.
Price Target Changed • Jun 14Price target decreased to ₹5,201Down from ₹5,647, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹4,149. Stock is down 25% over the past year. The company posted earnings per share of ₹134 last year.
Reported Earnings • May 15Full year 2026 earnings released: EPS: ₹158 (vs ₹168 in FY 2025)Full year 2026 results: EPS: ₹158 (down from ₹168 in FY 2025). Revenue: ₹25.2b (up 10% from FY 2025). Net income: ₹7.22b (down 5.9% from FY 2025). Profit margin: 29% (down from 34% in FY 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 9% per year.
Buy Or Sell Opportunity • May 14Now 21% overvaluedOver the last 90 days, the stock has fallen 7.1% to ₹4,681. The fair value is estimated to be ₹3,855, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 8.5% in the next 2 years.
お知らせ • May 13Pfizer Limited announces Annual dividend, payable on August 27, 2026Pfizer Limited announced Annual dividend of INR 75.0000 per share payable on August 27, 2026, ex-date on July 17, 2026 and record date on July 17, 2026.
Reported Earnings • Feb 10Third quarter 2026 earnings released: EPS: ₹40.42 (vs ₹27.89 in 3Q 2025)Third quarter 2026 results: EPS: ₹40.42 (up from ₹27.89 in 3Q 2025). Revenue: ₹6.83b (up 27% from 3Q 2025). Net income: ₹1.42b (up 11% from 3Q 2025). Profit margin: 21% (down from 24% in 3Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 20Pfizer Limited Announces Senior Management Personnel ChangesPfizer Limited announced the appointment of Mr. Nilesh Pendse as Category Lead – Vaccines of the Company with effect from February 1, 2026. Mr. Pendse shall accordingly be a Senior Management Personnel of the company effective the said date. Mr. Pendse joined Pfizer Products India Private Limited in 2024, where he led the Oncology Business, focusing on strategic growth, market access, and stakeholder engagement to advance cancer care. Prior to joining Pfizer Products India Private Limited, Mr. Pendse held leadership roles at Boehringer Ingelheim and Novartis where he managed diabetes and neurosciences Divisions, with a focus on sales, marketing, and franchise operations. In addition, Mr. Pendse comes from consulting background experience with firms such as Boston Consulting Group, Ernst & Young (EY) and Accenture, where he led projects related to strategy, revenue acceleration, and business transformation. Mr. Nilesh Pendse holds an MBA in Marketing from Jamnalal Bajaj Institute of Management Studies and a Bachelor’s degree in Electronics Engineering from the University of Mumbai. The company also announced that Mr. Manikantan Seshadrinathan – Category Lead, Hospitals & Rare Disease will transition to another role within the Pfizer Group Companies effective February 1, 2026, and shall accordingly cease to be a Senior Management Personnel of the Company effective January 31, 2026. Mr. Prashant Mahalingam, Category Lead – Internal Medicine, will take up additional responsibility of the Hospitals Business of the Company and shall be redesignated as Category Lead – Internal Medicine & Hospitals, effective February 1, 2026.
分析記事 • Dec 30Pfizer Limited's (NSE:PFIZER) Price Is Out Of Tune With EarningsWith a median price-to-earnings (or "P/E") ratio of close to 25x in India, you could be forgiven for feeling...
分析記事 • Nov 25Pfizer's (NSE:PFIZER) Solid Profits Have Weak FundamentalsPfizer Limited's ( NSE:PFIZER ) robust earnings report didn't manage to move the market for its stock. Our analysis...
New Risk • Nov 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Nov 13Second quarter 2026 earnings released: EPS: ₹41.32 (vs ₹34.61 in 2Q 2025)Second quarter 2026 results: EPS: ₹41.32 (up from ₹34.61 in 2Q 2025). Revenue: ₹6.42b (up 9.1% from 2Q 2025). Net income: ₹1.89b (up 19% from 2Q 2025). Profit margin: 29% (up from 27% in 2Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
分析記事 • Sep 13Pinning Down Pfizer Limited's (NSE:PFIZER) P/E Is Difficult Right NowWith a median price-to-earnings (or "P/E") ratio of close to 28x in India, you could be forgiven for feeling...
Reported Earnings • Aug 14First quarter 2026 earnings released: EPS: ₹41.91 (vs ₹32.94 in 1Q 2025)First quarter 2026 results: EPS: ₹41.91 (up from ₹32.94 in 1Q 2025). Revenue: ₹6.03b (up 7.1% from 1Q 2025). Net income: ₹1.92b (up 27% from 1Q 2025). Profit margin: 32% (up from 27% in 1Q 2025). Revenue is forecast to grow 7.5% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 8% per year.
New Risk • Jul 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.3% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.3% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
お知らせ • Jul 02Pfizer Limited Announces Directorate ChangesPfizer Limited announced that Ms. Shilpi Singh, Director - People Experience has tendered her resignation from the services of the Company with effect from August 14, 2025 (close of business), to pursue opportunities outside Pfizer Limited. Ms. Singh shall accordingly cease to be a Senior Management Personnel effective the said date. It is further informed that the Board of Directors, upon recommendation of the Nomination & Remuneration Committee has appointed Ms. Reshma Parida, currently the Senior Director- People Experience for APAC & AfME and SBO APAC Cluster, as Senior Director - People Experience of the Company with effect from August 1, 2025. Ms. Reshma Parida shall be a Senior Management Personnel of the Company, effective the said date. Ms. Parida is an accomplished professional with close to 3 decades of expertise in Human Resources field. Ms. Parida's areas of expertise include strategic business partnership, transformation management, organization design and effectiveness, talent and leadership coaching, diversity and inclusion, employee engagement, mergers and acquisitions, execution excellence, and well-being. Ms. Parida has undertaken varied roles of increasing responsibilities in Pfizer for about 5 years in the People Experience function. Ms. Parida began her career in Pfizer as Regional HR Lead for APAC region in August 2020 and has taken up the additional responsibility of HR Lead for Global API, SBO APAC Cluster and Global Small Molecule Operations from 2021. In her current role in Pfizer Global Supply (PGS), she leads the People Experience function for APAC & AfME Region and SBO APAC Cluster. Prior to her role with Pfizer, Ms. Parida has held senior positions at Teva Pharmaceuticals, Bristol Myers Squibb, and Mylan Pharmaceuticals. Ms. Reshma Parida holds a Bachelor of Science degree from Fergusson College, Pune, and a Masters' degree in Personnel Management from Pune University.
Reported Earnings • Jul 02Full year 2025 earnings released: EPS: ₹168 (vs ₹121 in FY 2024)Full year 2025 results: EPS: ₹168 (up from ₹121 in FY 2024). Revenue: ₹22.8b (up 4.0% from FY 2024). Net income: ₹7.68b (up 39% from FY 2024). Profit margin: 34% (up from 25% in FY 2024). Revenue is forecast to grow 7.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jun 30+ 2 more updatesPfizer Limited to Report Q4, 2026 Results on May 30, 2026Pfizer Limited announced that they will report Q4, 2026 results on May 30, 2026
分析記事 • May 28Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 28%The Pfizer Limited ( NSE:PFIZER ) share price has done very well over the last month, posting an excellent gain of 28...
分析記事 • May 26Pfizer (NSE:PFIZER) Posted Healthy Earnings But There Are Some Other Factors To Be Aware OfUnsurprisingly, Pfizer Limited's ( NSE:PFIZER ) stock price was strong on the back of its healthy earnings report...
Valuation Update With 7 Day Price Move • May 26Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹5,148, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 24% over the past three years.
お知らせ • May 20+ 2 more updatesPfizer Limited, Annual General Meeting, Jul 21, 2025Pfizer Limited, Annual General Meeting, Jul 21, 2025.
Reported Earnings • May 20Full year 2025 earnings released: EPS: ₹168 (vs ₹121 in FY 2024)Full year 2025 results: EPS: ₹168 (up from ₹121 in FY 2024). Revenue: ₹24.5b (up 12% from FY 2024). Net income: ₹7.68b (up 39% from FY 2024). Profit margin: 31% (up from 25% in FY 2024). Revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 5% per year and the company’s share price has also increased by 5% per year.
分析記事 • Mar 03Pfizer Limited's (NSE:PFIZER) Share Price Not Quite Adding UpWhen close to half the companies in India have price-to-earnings ratios (or "P/E's") below 24x, you may consider Pfizer...
お知らせ • Feb 14Pfizer Limited Announces Completion of Second Term for Sunil Lalbhai as an Independent Director, Chairman of the Stakeholders' Relationship Committee and Risk Management Committee and Member of the Audit CommitteePfizer Limited announced that Mr. Sunil Lalbhai has completed his second term as an Independent Director of the Company with effect from the end of the day on February 13, 2025. Consequent to Mr. Lalbhai's completion of term as an Independent Director, he ceased to be the Chairman of the Stakeholders' Relationship Committee and Risk Management Committee and Member of the Audit Committee.
Reported Earnings • Feb 01Third quarter 2025 earnings released: EPS: ₹27.89 (vs ₹28.42 in 3Q 2024)Third quarter 2025 results: EPS: ₹27.89 (down from ₹28.42 in 3Q 2024). Revenue: ₹5.81b (up 7.6% from 3Q 2024). Net income: ₹1.28b (down 1.8% from 3Q 2024). Profit margin: 22% (down from 24% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has remained flat.
お知らせ • Jan 31Pfizer Limited Announces Resignation of Amit Sharma as DirectorPfizer Limited announced resignation of Mr. Amit Sharma, as Director effective from close of business hours on January 31, 2025, to pursue opportunities outside Pfizer.
お知らせ • Jan 18FeganScott Announces Class-Action Lawsuit Against Pfizer and ViatrisCalifornia woman has filed a class-action lawsuit claiming pharmaceutical giants Pfizer (PFE) and Viatris (VTRS), among others, manufactured and sold Depo-Provera, one of the most widely used forms of hormonal contraception, despite knowledge that it causes brain tumors. According to the complaint, studies dating back to the 1980s have shown a connection between hormones and brain tumors called intracranial meningiomas that the pharmaceutical giants should have known about. A March 2024 study published in the British Medical Journal cemented a positive correlation between medroxyprogesterone acetate (MPA), the synthetic hormone found in Depo-Provera, and the tumors. The study found that women using Depo-Provera are five times more likely to develop intracranial meningiomas when used for more than one year. The complaint states that at times, nearly a quarter of all sexually active women in the United States used Depo-Provera. Use of the popular contraceptive has historically been highest among women in at-risk populations, as it is relatively low-cost and less burdensome compared to other contraceptives. The suit cites a body of scientific studies published between the 1980s and 2024 that link Depo-Provera to the development of intracranial meningiomas, which FeganScott Attorney Lynn Ellenberger says both the brand and generic manufacturers should have been aware of and acted upon. The lawsuit, filed in the federal court in the Western District of Pennsylvania, seeks to establish a medical monitoring program for those in certain states who have received the Depo-Provera injection for at least one year. Individuals interested in learning more about their legal options are urged to contact FeganScott.
分析記事 • Nov 28Some Confidence Is Lacking In Pfizer Limited's (NSE:PFIZER) P/EPfizer Limited's ( NSE:PFIZER ) price-to-earnings (or "P/E") ratio of 39.3x might make it look like a sell right now...
お知らせ • Nov 15Pfizer Limited Appoints Mr. Chetan Solse as India Legal Lead, Effective November 18, 2024Pfizer Limited informed that the Board of Directors of the Company, upon recommendation of the Nomination and Remuneration Committee has appointed Mr. Chetan Solse as India Legal Lead of the Company effective November 18, 2024. Accordingly, Mr. Chetan Solse shall be a Senior Management Personnel of the Company effective November 18, 2024. Mr. Solse holds a Bachelor's Degree in Commerce and Law from the University of Mumbai and is a certified member of the Institute of Company Secretaries of India (ICSI) and the Institute of Chartered Secretaries and Administrators (ICSA), UK. Mr. Solse is an accomplished legal counsel with over two decades of expertise in corporate legal advisory, litigation management, ethics & compliance, and risk management particularly within the healthcare and FMCG sectors. Mr. Solse joins the Company from Roche Diagnostics India Private Limited where he served as Head Legal & Risk Management (India & Neighboring Markets). Prior to his role with Roche Diagnostics India Private Limited, Mr. Solse has held senior positions at Parle Agro Private Limited, Diageo India Private Limited and Edwards Life Sciences (India) Private Limited.
お知らせ • Nov 11Pfizer Limited Announces Board and Committee ChangesPfizer Limited announced that Mr. Pradip Shah and Mr. Uday Khanna, have completed their term as Independent Directors of the Company with effect from the end of the day on November 9, 2024. Consequent to Mr. Khanna's completion of term as an Independent Director, he ceased to be the Chairman of the Audit Committee and Nomination & Remuneration Committee and Member of the Stakeholders' Relationship Committee. an intimation was given that the Board of Directors of the Company, upon recommendation of the Nomination and Remuneration Committee, had appointed Mr. Pradip Shah as a Non-Executive Non-Independent Director with effect from November 10, 2024, liable to retire by rotation. It may also be noted that the said appointment was approved by the shareholders of the Company at the 73 Annual General Meeting of the Company held on August 28, 2024. Mr. Pradip Shah shall continue to be the Chairman of the Board of Directors, Corporate Social Responsibility Committee and a Member of the Audit Committee and the Nomination and Remuneration Committee. Mr. Pradip Shah is the founder and Chairman of IndAsia Fund Advisors Private Limited. He is also the co-founder of www.Grow-Trees.com. Mr. Pradip Shah holds an MBA from the Harvard Business School. He is also a Chartered Accountant and a Cost Accountant and ranked first in India in the Chartered Accountancy Examination. Mr. Shah is the ex-Managing Director of CRISIL, India's first and the largest credit rating agency. Prior to founding CRISIL, Mr. Pradip Shah assisted in founding the Housing Development Finance Corporation (HDFC) in 1977. Mr. Shah has also served as a consultant to USAID, the World Bank and the Asian Development Bank. He has also a member /Chairman of various prestigious committees/commissions such as Banks Board Bureau, IFSC International Retail Business Development Committee, Western Region Board of Reserve Bank of India. Mr. Shah is a Director on the Board of several reputed companies including Kansai Nerolac Paints Limited, Sonata Software Limited, BASF (India) Limited, Bajaj Auto Limited.
お知らせ • Nov 05Pfizer Limited Announces Executive Appointments, Effective November 7, 2024Pfizer Limited announced Mr. Deepak Rakheja, Category Lead Internal Medicine has been appointed as Strategic Partnerships, Channel Development and International Neighbouring Markets Lead, effective November 7, 2024. Mr. Rakheja shall continue to be a Senior Management Personnel. Mr. Deepak Rakheja holds Master's in Business Administration Degree from HEC Paris Business School. Mr. Rakheja also holds a Master of Economics Degree from University of Delhi. Mr. Deepak Rakheja has during his 15 years of tenure with Pfizer, helmed roles of increased scope, responsibility & complexity, including Category Lead Internal Medicine, Commercial roles, Sales Logistics & Demand Management, Business Operations, Field Force Effectiveness, Training, and Commercial Compliance. Mr. Rakheja also lead Pfizer's Global Commercial Operations (GCO) for Africa, Middle East & India. Prior to this he had also served as the Commercial Director for Growth Markets (Iran, Iraq, Syria & Yemen) and the Strategic Alliances Gulf Levant Markets. The company also announced appointment of Mr. Prashant Mahalingam as Category Lead Internal Medicine effective November 7, 2024. Mr. Prashant Mahalingam shall be a Senior Management Personnel effective the said date. Mr. Prashant Mahalingam holds a Bachelors in Technology (Chemical Engineering) from IIT Madras, Post Graduate Degree in Management from IIM Calcutta and Executive Education Innovation Consortium from Tuck School of Business, University of Dartmouth. Mr. Mahalingam is a versatile and transformative business leader with over 25 years of experience across General Management, Sales, Marketing, Human Resources, Supply Chain, Digital Transformation, Analytics, and E-Commerce, primarily in the FMCG and Pharmaceutical sectors. Mr. Mahalingam joins the Company from Dr. Reddy's Laboratories Limited (DRL), where he served as the Cluster Head for the Acute Therapies (RX) and Consumer Health business. Prior to his role with DRL Mr. Mahalingam served as Commercial Head for Johnson & Johnson's Consumer health business in Malaysia and Singapore markets. Mr. Mahalingam has significant experience in leading large teams, turning around businesses to deliver market-beating and sustainable growth, and spearheading new innovation-led digital ventures.
Reported Earnings • Oct 29Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024)Second quarter 2025 results: EPS: ₹34.61 (up from ₹32.56 in 2Q 2024). Revenue: ₹5.89b (up 2.3% from 2Q 2024). Net income: ₹1.58b (up 6.3% from 2Q 2024). Profit margin: 27% (up from 26% in 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has increased by 1% per year.
Board Change • Sep 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Non-Executive Independent Director Lakshmanan Kumar was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Aug 31We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its DebtLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
お知らせ • Aug 30Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024Pfizer Limited approved to declare a dividend of INR 35 (350%) per equity share for the financial year ended March 31, 2024, at its AGM held on August 28, 2024.
Declared Dividend • Aug 09Dividend of ₹35.00 announcedShareholders will receive a dividend of ₹35.00. Ex-date: 21st August 2024 Payment date: 6th September 2024 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by both earnings (29% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has increased by an average of 12% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 12% over the next year, which should provide support to the dividend and adequate earnings cover.
お知らせ • Aug 08Pfizer Limited, Annual General Meeting, Aug 28, 2024Pfizer Limited, Annual General Meeting, Aug 28, 2024, at 15:00 Indian Standard Time.
お知らせ • Aug 07+ 2 more updatesPfizer Limited to Report Q2, 2025 Results on Nov 14, 2024Pfizer Limited announced that they will report Q2, 2025 results on Nov 14, 2024
分析記事 • Aug 07Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%Despite an already strong run, Pfizer Limited ( NSE:PFIZER ) shares have been powering on, with a gain of 25% in the...
Price Target Changed • Aug 01Price target increased by 11% to ₹5,477Up from ₹4,953, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of ₹5,640. Stock is up 41% over the past year. The company is forecast to post earnings per share of ₹139 for next year compared to ₹121 last year.
Reported Earnings • Jul 30First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)First quarter 2025 results: EPS: ₹32.94 (up from ₹20.44 in 1Q 2024). Revenue: ₹6.05b (up 14% from 1Q 2024). Net income: ₹1.51b (up 61% from 1Q 2024). Profit margin: 25% (up from 18% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 2% per year.
お知らせ • Jul 22Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024Pfizer Limited announced that they will report Q1, 2025 results on Jul 29, 2024
分析記事 • May 25Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)Pfizer Limited's ( NSE:PFIZER ) recent weak earnings report didn't cause a big stock movement. Our analysis suggests...
Reported Earnings • May 18Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)Full year 2024 results: EPS: ₹121 (down from ₹136 in FY 2023). Revenue: ₹23.7b (down 2.1% from FY 2023). Net income: ₹5.51b (down 12% from FY 2023). Profit margin: 23% (down from 26% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • May 18Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024Pfizer Limited announced that at its Board of Directors has at its Meeting held on May 17, 2024, recommended a dividend of INR 35/- per equity share of INR 10/- each (350%) for the financial year ended March 31, 2024. The said dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 6, 2024.
お知らせ • May 08Pfizer Limited to Report Q4, 2024 Results on May 17, 2024Pfizer Limited announced that they will report Q4, 2024 results on May 17, 2024
お知らせ • Apr 03+ 1 more updatePfizer Limited Appoints Amit Agarwal as Chief Financial OfficerPfizer Limited announced the appointment of Mr. Amit Agarwal as a Whole-time Director of the Company designated as Executive Director Finance & Chief Financial Officer for a period of 5 years with effect from February 26, 2024, by way of an `Ordinary Resolution'.
お知らせ • Mar 28China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder CancerAstellas Pharma Inc. announced that on March 27, 2024 the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the supplemental Biologics License Application (sBLA) for enfortumab vedotin with KEYTRUDA (pembrolizumab) as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). If approved, enfortumab vedotin with KEYTRUDA has the potential to change the treatment paradigm, becoming the first combination treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC. Urothelial cancer (UC) encompasses cancers of both the lower urinary tract (bladder and urethra) and upper tract (ureter and renal pelvis), with disease that originates in the lower tract accounting for 90% to 95% of all UC cases. Globally, approximately 614,000 new cases of bladder cancer and approximately 220,000 deaths are reported annually. It is estimated that approximately 93,000 people in China were diagnosed with bladder cancer and approximately 41,000 deaths were reported in 2022. The sBLA for the first-line use of this combination is based on results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39). The study found that the combination improved overall survival (OS) and progression-free survival (PFS) with statistically significant and clinically meaningful results in patients with previously untreated la/mUC compared to platinum-containing chemotherapy. The safety results were consistent with those previously reported with this combination, and no new safety issues were identified. The NMPA is also reviewing enfortumab vedotin as a treatment for patients with locally advanced or metastatic urothelial cancer (la/mUC) who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency is reviewing the enfortumab vedotin in combination with pembrolizumab therapy, as well as Japan's Ministry of Health, Labour and Welfare (MHLW). The U.S. Food and Drug Administration approved the combination therapy in December 2023.
分析記事 • Feb 13Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)Third quarter 2024 results: EPS: ₹28.42 (down from ₹32.93 in 3Q 2023). Revenue: ₹5.76b (down 7.4% from 3Q 2023). Net income: ₹1.30b (down 14% from 3Q 2023). Profit margin: 23% (down from 24% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.
お知らせ • Feb 09Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024Pfizer Limited informed that Mr. Satyen Amin, Lead - Market Access has tendered his resignation from employment of the Company with effect from March 31, 2024, to pursue an opportunity outside Pfizer Limited. Mr. Satyen Amin shall accordingly cease to be a Senior Management Personnel effective the said date.
お知らせ • Feb 01Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024Pfizer Limited announced that they will report Q3, 2024 results on Feb 09, 2024
分析記事 • Jan 17Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share PriceWith a price-to-earnings (or "P/E") ratio of 37.4x Pfizer Limited ( NSE:PFIZER ) may be sending bearish signals at the...
お知らせ • Nov 17Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023Pfizer Limited informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company appointed Ms. Aditi Mehta as Category Lead, Vaccines effective December 1, 2023. Accordingly, Ms. Aditi Mehta shall be a Senior Management Personnel effective the said date. Ms. Aditi Mehta is a Gold Medalist in Bachelor of Pharmacy from K.M Kundnani College of Pharmacy, Mumbai. Ms. Aditi Mehta is a seasoned pharmaceutical professional with over 13 years of experience in pharmaceutical marketing, strategy & research. Ms. Mehta had a decade long stint with Pfizer Products India Pvt. Ltd., (Pfizer Inc.'s wholly owned subsidiary in India) where she held positions of increasing responsibilities. In her role as Category Lead for Oncology business, she was responsible for the development and execution of the strategy for the Oncology portfolio for India market. Prior to this, Ms. Mehta had a two-year stint with Bristol Myers Squibb as a Business Analyst. Ms. Mehta is proud receipt of various accolades and awards, including the Medico-Marketing Excellence Award 2017 by Pfizer India Country Leadership, PfizerGlobal Commercial Award in 2019 for Breast Cancer Access initiatives in India, e4M Health & Wellness Marketing Award 2023 for World Cancer Day Awareness Campaign. Most recently, she has also been selected among the Top 100 Inspiring Women Leaders in Pfizer.
お知らせ • Nov 15Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023Pfizer Limited announced that Mr. Milind Patil has resigned as a Director on the Board with effect from close of business on November 13, 2023, consequent to the expiry of his 5 year term as Executive Director - Finance effective the said date and his upcoming retirement from the services of the Company effective November 30, 2023. Pursuant to the above, Mr. Patil shall cease to be a Member of the Corporate Social Responsibility Committee, Risk Management Committee and Board Administrative & Share Transfer Committee of the Board effective close of business on November 13, 2023. It may be noted that Mr. Patil shall continue to serve as the Chief Financial Officer of the Company until his retirement on November 30, 2023.
お知らせ • Oct 29Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of DirectorsPfizer Limited announced that Mr. Samir Kazi has resigned as a Director from the Board of Directors of the Company effective close of business September 12, 2023. to pursue an opportunity outside Pfizer Limited. Consequently, Mr. Samir Kazi has resigned as a Director from the Board of Directors of the Company, with effect from the close of business on September 12, 2023. Pursuant to the above, Mr. Kazi shall cease to be a Member of the Corporate Social Responsibility Committee, Stakeholders' Relationship Committee and Board Administrative & Share Transfer Committee of the Board effective close of business on September 12, 2023. The effective date of resignation of Mr. Samir Kazi as an employee shall be from such date as may be mutually agreed between the Company and Mr. Kazi.
Reported Earnings • Oct 29Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)Second quarter 2024 results: EPS: ₹32.56 (down from ₹67.99 in 2Q 2023). Revenue: ₹6.11b (down 4.1% from 2Q 2023). Net income: ₹1.49b (down 52% from 2Q 2023). Profit margin: 24% (down from 49% in 2Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 8.7% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
お知らせ • Oct 19Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023Pfizer Limited announced that they will report Q2, 2024 results on Oct 28, 2023
お知らせ • Sep 07Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner LeadPfizer Limited informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has appointed Mr. Chaitanya Nadkarni as India Digital Client Partner Lead effectiveSeptember 11, 2023. Accordingly, Mr. Chaitanya Nadkarni shall be a Senior Management Personnel effective the said date. Mr. Chaitanya Nadkarni brings over 26 years of experience in the field of IT and Digital solutions. During his 11 years tenure in Novartis Healthcare he has been instrumental in devising IT Roadmaps for various countries in alignment with business initiatives and Global/Regional (Asia Pacific, Middle East & Africa) IT & Digital Strategy. He rolled out several digital tools to the Marketing and Sales teams for impactful omni-channel engagement with HCPs. Mr. Chaitanya Nadkarni had also established a Digital Governance Process, Asset Roll-out management and created awareness about Information Security through internal campaigns. Mr. Chaitanya Nadkarni holds a bachelor's degree in Engineering and a MBA in Marketing. Mr. Chaitanya Nadkarni has extensively worked in various industries such as IT, Insurance, Consulting and has been with Pharmaceutical Industry for over 12 plus years.
お知らせ • Aug 22Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023Pfizer Limited announced that at its Annual General Meeting of the Company held on August 18, 2023, approved to declare a final dividend of INR 40 (400%) per equity share for the financial year ended March 31, 2023.
New Risk • Aug 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.1% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results.
お知らせ • Aug 18Pfizer Limited Announces Change in Management, Effective September 1, 2023Pfizer Limited announced that Mr. Manish Mishra Category Lead, Vaccines will be transitioning to a different role within Pfizer Group effective September 1, 2023, and shall accordingly cease to be a Senior Management Personnel effective the said date. Ms. Sudeshna Mitra Healthcare Solutions Partner Lead will be moving to a different role within the Company effective September 1, 2023, and shall accordingly cease to be a Senior Management Personnel from the said date.
お知らせ • Aug 05Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023Pfizer Limited announced that they will report Q1, 2024 results on Aug 11, 2023
Upcoming Dividend • Aug 04Upcoming dividend of ₹40.00 per share at 0.9% yieldEligible shareholders must have bought the stock before 11 August 2023. Payment date: 16 September 2023. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.5%). In line with average of industry peers (0.9%).
Reported Earnings • Jul 29Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)Full year 2023 results: EPS: ₹136 (up from ₹134 in FY 2022). Revenue: ₹24.2b (down 7.1% from FY 2022). Net income: ₹6.24b (up 1.9% from FY 2022). Profit margin: 26% (up from 24% in FY 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Jul 29Pfizer Limited, Annual General Meeting, Aug 18, 2023Pfizer Limited, Annual General Meeting, Aug 18, 2023, at 14:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statement of the Company for the financial year ended March 31, 2023, including the Reports of the Board of Directors and Auditors thereon; to declare a final dividend of INR 40/- (400%) per equity share for the financial year ended March 31, 2023; to consider appointment of a Director in place of Mr. Samir Kazi (DIN: 07184083), who retires by rotation and being eligible, offers himself for re-appointment; to consider revision in the limit of commission payable to Non-executive Directors; and to consider and ratify the remuneration payable to Messrs. RA & co., cost Accountants for the financial year ending March 31, 2024.
お知らせ • Jul 28Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023Pfizer Limited proposed final dividend of INR 40 (400%) per equity share for the financial year ended March 31, 2023.
お知らせ • May 19Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm InjectionsPfizer Limited has decided to initiate a voluntary recall of(i) Magnex 1gm, 2gm; (ii) Magnex Forte 1.5gm, 3gm; (iii) Zosyn 4.5gm; and (iv) Magnamycin 250mg, 1gm, 2gm injections manufactured by Astral SteriTech Private Limited ("Astral") and marketed/distributed by Pfizer Limited ("the Company"). Pfizer places the utmost emphasis on patient safety and product quality at every step in the manufacturing and supply chain process. The Company was informed by its contract manufacturer in India, Astral SteriTech Private Ltd, that it has observed an out-of-specification during a routine environmental monitoring of its manufacturing block. Astral manufactures three products for Pfizer, namely, Magnex, Magnamycin and Zosyn. While this issue is presently being investigated, out of an abundance of caution, Pfizer has decided to voluntarily recall from the market, all batches of these three products. Pfizer is taking all necessary steps to resolve the situation. The above voluntary recall is likely to have an impact on the revenue and profitability of the Company. The said Products recorded a sale of INR 1,390 million for the year ended on March 31, 2023.
Price Target Changed • May 17Price target decreased by 7.9% to ₹4,595Down from ₹4,988, the current price target is an average from 5 analysts. New target price is 20% above last closing price of ₹3,817. Stock is down 11% over the past year. The company posted earnings per share of ₹136 last year.
お知らせ • May 16+ 1 more updatePfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023Pfizer Limited the Board of Directors meeting held on May 15, 2023, recommended a final dividend of INR 35 per equity share of INR 10 each (350%) for the financial year ended March 31, 2023. The said final dividend, if declared at the ensuing Annual General Meeting of the Company shall be paid on or before September 16, 2023.
Reported Earnings • May 16Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)Full year 2023 results: EPS: ₹136 (up from ₹134 in FY 2022). Revenue: ₹25.3b (down 3.3% from FY 2022). Net income: ₹6.24b (up 1.9% from FY 2022). Profit margin: 25% (up from 23% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • May 06Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023Pfizer Limited announced that they will report fiscal year 2023 results on May 15, 2023
分析記事 • Mar 15Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt ResponsiblyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)Third quarter 2023 results: EPS: ₹32.93 (up from ₹31.46 in 3Q 2022). Revenue: ₹6.22b (down 8.0% from 3Q 2022). Net income: ₹1.51b (up 4.7% from 3Q 2022). Profit margin: 24% (up from 21% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Feb 10+ 2 more updatesPfizer India Appoints Meenakshi Nevatia as CEOPfizer India has announced the appointment of Meenakshi Nevatia as its new CEO and Managing Director, effective from 3 April, 2023. Nevatia will serve in this role for the next five years. Meenakshi Nevatia has been in the healthcare, medical technology, and pharmaceutical industries for over 25 years, holding various key global leadership positions. She is recognised as a medical device leader and has a strong passion for improving healthcare. In her previous role as Vice President and Managing Director of Stryker India, Nevatia was responsible for building the company's business strategy and setting it up for long-term growth in the Indian market. Last year in August, she was appointed as the chairperson for India Executive Committee of the Asia Pacific Medical Technology Association (APACMed).
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)Second quarter 2023 results: EPS: ₹67.99 (up from ₹31.25 in 2Q 2022). Revenue: ₹6.37b (flat on 2Q 2022). Net income: ₹3.11b (up 118% from 2Q 2022). Profit margin: 49% (up from 23% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Executive Director of Legal & Executive Director Samir Kazi was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 13Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)Second quarter 2023 results: EPS: ₹67.99 (up from ₹31.25 in 2Q 2022). Revenue: ₹6.62b (up 4.0% from 2Q 2022). Net income: ₹3.11b (up 118% from 2Q 2022). Profit margin: 47% (up from 23% in 2Q 2022). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year.
Upcoming Dividend • Sep 12Upcoming dividend of ₹30.00 per shareEligible shareholders must have bought the stock before 19 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.6%). Lower than average of industry peers (1.0%).
Upcoming Dividend • Aug 11Upcoming dividend of ₹35.00 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 23 September 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of Indian dividend payers (1.7%). Lower than average of industry peers (1.0%).
Reported Earnings • Aug 06First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: ₹6.11b (down 19% from 1Q 2022). Net income: ₹325.5m (down 84% from 1Q 2022). Profit margin: 5.3% (down from 27% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 12% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Aug 05+ 1 more updatePfizer Limited to Report Q4, 2023 Results on May 29, 2023Pfizer Limited announced that they will report Q4, 2023 results on May 29, 2023
分析記事 • Jul 20A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)How far off is Pfizer Limited ( NSE:PFIZER ) from its intrinsic value? Using the most recent financial data, we'll take...
Buying Opportunity • Jul 12Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 6.9%. The fair value is estimated to be ₹5,170, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Earnings per share has grown by 9.3%.
Price Target Changed • Jun 14Price target decreased to ₹5,201Down from ₹5,647, the current price target is provided by 1 analyst. New target price is 25% above last closing price of ₹4,149. Stock is down 25% over the past year. The company posted earnings per share of ₹134 last year.
Buying Opportunity • Jun 08Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 6.6%. The fair value is estimated to be ₹5,160, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.8% over the last 3 years. Earnings per share has grown by 9.3%.